Premium
O4‐04‐05: Aducanumab (BIIB037), an anti‐amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer's disease: Interim results of a randomized, double‐blind, placebo‐controlled, phase 1b study
Author(s) -
Sevigny Jeff,
Chiao Ping,
Williams Leslie,
Chen Tianle,
Ling Yan,
O'Gorman John,
Hock Christoph,
Nitsch Roger M.,
Sandrock Alfred
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.07.367
Subject(s) - tolerability , placebo , clinical endpoint , medicine , interim analysis , pharmacodynamics , clinical trial , adverse effect , pharmacokinetics , pathology , alternative medicine
statistically significant treatment differences for t-tau or p-tau in any population. Conclusions:Amyloid PET GCA SUVr decreases 10mg pooled dose suggests target engagement. There was no effect on neuronal injury biomarkers (p-tau and t-tau). Greater brain volume decreases in the MTM treatment groups was consistent with prior AD immunotherapy trials but the absence of treatment related differences in the small eAD study should be interpreted with caution.